ReviewClinical pharmacology and therapeutics2014
Immunologic and clinical effects of targeting PD-1 in lung cancer.
Review in Clinical pharmacology and therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review.Journal of the National Cancer Institute · 2021Pooled it
- Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.The oncologist · 2020Trial
- Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer.The oncologist · 2016Trial
- A Retrospective Study of First-Line Immunotherapy for Advanced Non-Small Cell Lung Cancer in the Elderly.Aging medicine (Milton (N.S.W)) · 2025Article
- Development of a human phage display-derived anti-PD-1 scFv antibody: an attractive tool for immune checkpoint therapy.BMC biotechnology · 2022Article
- Paliperidone Inhibits Glioblastoma Growth in Mouse Brain Tumor Model and Reduces PD-L1 Expression.Cancers · 2021Article
- Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.The oncologist · 2020Review
- Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies.Cancers · 2020Review
- Article
- Genomic signatures defining responsiveness to allopurinol and combination therapy for lung cancer identified by systems therapeutics analyses.Molecular oncology · 2019Article
- Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma.Journal of thoracic disease · 2019Review
- Immune checkpoint inhibitors in cancer therapy.Journal of biomedical research · 2018Article
- The Role of Cytochromes P450 in Infection.Frontiers in immunology · 2018Review
- Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma.Frontiers in pharmacology · 2018Article
- Clinical observation of immune checkpoint inhibitors in the treatment of advanced pancreatic cancer: a real-world study in Chinese cohort.Therapeutics and clinical risk management · 2018Article
- Anti-PD-1 Antibody Treatment Promotes Clearance of Persistent Cryptococcal Lung Infection in Mice.Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence.Therapeutic advances in respiratory disease · 2017Review
- Current state of immunotherapy for non-small cell lung cancer.Translational lung cancer research · 2017Review
- Advanced Care Provider and Nursing Approach to Assessment and Management of Immunotherapy-Related Dermatologic Adverse Events.Journal of the advanced practitioner in oncology · 2017Review
- Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives.OncoTargets and therapy · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapeutic antibodies that block the programmed cell death protein-1 (PD-1) immune checkpoint pathway prevent T-cell downregulation and promote immune responses against cancer. Several PD-1 pathway inhibitors have shown robust activity in initial trials. This article reviews the preclinical evidence, rationale, and clinical pharmacology of blockade of PD-1 or its ligands as therapy for lung cancer and provides an overview of agents in development, clinical evidence to date, and implications for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.